Recro Pharma Reports Second Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Recro Pharma Reports Second Quarter 2019 Financial Results

Recro Pharma (REPH) Tops Q2 EPS by 29c, Revenues Beat; Raises FY19 Revenue Guidance

August 8, 2019 7:17 AM EDT

Recro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.13), $0.29 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $31.26 million versus the consensus estimate of $23.59 million.

Our CDMO business has delivered record results, generating $56.3 million in year to date revenues, a 36% increase from the comparable six-month period in 2018, said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. We are very pleased with the sales... More